en
Scientific article
English

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98

Published inJournal of clinical oncology, vol. 28, no. 29, p. 4480-4484
Publication date2010
Abstract

PURPOSE: We report the long-term results of a randomized clinical trial comparing induction therapy with once per week for 4 weeks single-agent rituximab alone versus induction followed by 4 cycles of maintenance therapy every 2 months in patients with follicular lymphoma. PATIENTS AND METHODS: Patients (prior chemotherapy 138; chemotherapy-naive 64) received single-agent rituximab and if nonprogressive, were randomly assigned to no further treatment (observation) or four additional doses of rituximab given at 2-month intervals (prolonged exposure). RESULTS: At a median follow-up of 9.5 years and with all living patients having been observed for at least 5 years, the median event-free survival (EFS) was 13 months for the observation and 24 months for the prolonged exposure arm (P < .001). In the observation arm, patients without events at 8 years were 5%, while in the prolonged exposure arm they were 27%. Of previously untreated patients receiving prolonged treatment after responding to rituximab induction, at 8 years 45% were still without event. The only favorable prognostic factor for EFS in a multivariate Cox regression was the prolonged rituximab schedule (hazard ratio, 0.59; 95% CI, 0.39 to 0.88; P = .009), whereas being chemotherapy naive, presenting with stage lower than IV, and showing a VV phenotype at position 158 of the Fc-gamma RIIIA receptor were not of independent prognostic value. No long-term toxicity potentially due to rituximab was observed. CONCLUSION: An important proportion of patients experienced long-term remission after prolonged exposure to rituximab, particularly if they had no prior treatment and responded to rituximab induction.

Keywords
  • Antibodies, Monoclonal/administration & dosage/*therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents/administration & dosage/therapeutic use
  • Disease-Free Survival
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Lymphoma, Follicular/*drug therapy
  • Middle Aged
  • Multivariate Analysis
  • Prognosis
  • Proportional Hazards Models
  • Prospective Studies
  • Remission Induction
  • Time Factors
  • Treatment Outcome
Citation (ISO format)
MARTINELLI, Giovanni et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. In: Journal of clinical oncology, 2010, vol. 28, n° 29, p. 4480–4484. doi: 10.1200/JCO.2010.28.4786
Main files (1)
Article
accessLevelRestricted
Identifiers
ISSN of the journal0732-183X
457views
0downloads

Technical informations

Creation05/23/2012 8:53:08 AM
First validation05/23/2012 8:53:08 AM
Update time03/14/2023 5:34:26 PM
Status update03/14/2023 5:34:25 PM
Last indexation02/12/2024 8:15:44 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack